The human p19(ARF) protein encoded by the β transcript of the p16(INK4a) gene is frequently lost in small cell lung cancer

Cancer Research

Volumn 58, Issue 17, 1998, Pages 3926-3931

  Gazzeri, Sylvie ^a   Della Valle, Veronique ^b   Chaussade, Laure ^a   Brambilla, Christian ^a   Larsen, Christian Jacques ^b   Brambilla, Elisabeth ^a,c  

^a INSTITUT ALBERT BONNIOT   (France)

^b INSERM   (France)

^c HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; MDM2 PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN; PROTEIN MDM2; PROTEIN P14ARF; PROTEIN P16INK4A;

ARTICLE; CONTROLLED STUDY; GENE LOSS; GENE REPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; CHEMISTRY; CHROMOSOME MAP; EXON; GENETICS; LUNG; LUNG TUMOR; PHYSIOLOGY; SMALL CELL CARCINOMA;

CARCINOMA, SMALL CELL; CHROMOSOME MAPPING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EXONS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032148385     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
2. INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene, 11: 21-29, 1995.
3. INK4A transcript. Cancer Res., 55: 2995-2997, 1995.
4. Stone, S., Jiang, P., Dayananth., P., Tavtigian, S. V., Katcher, H., Parry, D., Peters, G., and Kamb, A. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res., 55: 2988-2994, 1995.
5. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 993-100, 1995.
6. INK4A/MTS1/CDKN2 locus to human malignancies. In: Meijer L., Guidet S., and Philipp M. (eds.), Progress in Cell Cycle Research, Vol. 3, pp. 109-124. New York: Plenum Press, 1997.
7. Liggett, W. H., Sewell, D. A., Rocco, J., Ahrendt, S. A., Koch, W., and Sidransky, D. p16 and p16β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res., 56: 4119-4123, 1996.
8. Flores, J. F., Walker, G. J., Glendening, J. M., Haluska, F. G., Castresana, J. S., Rubio, M-P., Pastorfide, G. C., Boyer, L. A., Kao, W. H., Bulyk, M., Barnhill, R. L., Hayward, N. K., Housman, D. E., and Fountain, J. W. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res., 56: 5023-5032, 1996.
9. Halls, M., and Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res., 68: 67-108, 1996.
10. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, J., Harshman, K., Tavtigian, S. V., Stocjert, E., Day, R. S., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
11. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
12. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Isaacs, W., Koch, W., Schwab, D., and Sidransky, D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat. Genet., 11: 210-212, 1995.
13. Hebert, J., Cayuela, J. M., Berkeley, J., and Sigaux, F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias. Blood, 84: 4038-4044, 1994.
14. Cayuela, J. M., Hebert, J., and Sigaux, F. Homozygous MTS1 (p16INK4A) deletion in primary tumor cells of 163 leukemic patients. Blood, 85: 854, 1995.
15. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
16. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P. J., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
17. Gonzales-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Turnout, J. M., and Jones, P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
18. INK4a and p16β transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2 exon mutations. Oncogene, 15: 515-523, 1997.
19. ARF. Proc. Natl. Acad. Sci. USA, 94: 669-673, 1997.
20. ARF. Cell. 91: 649-659, 1997.
21. Fitzgerald, M. G., Harkin, D. P., Silva-Arrieta, S., Macdonald, D. J., Lucchina, L. C., Unsal, H., O'Neill, E., Koh, J., Finkelstein, D. M., Isselbacher, K. J., Sober, A. J., and Haber, D. A. Prevalence of germ-line mutations in p16. p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. Natl. Acad. Sci. USA, 93: 8541-8545, 1996.
22. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
23. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
24. Minna, J. D., Sekido, Y., Fong, K., and Gazdar, A. F. Molecular biology of lung cancer. In: V. T. DeVila, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 849-857. Philadelphia: Lippincott, 1997.
25. Gazzeri, S., Gouyer, V., Vourc'h, C. Brambilla, C., and Brambilla, E. Mechanisms of p16INK4A inactivation in non small cell lung cancer. Oncogene. 16: 497-505, 1998.
26. Brambilla, E., Moro, D., Veale, D., Brichon, P. Y., Stoebner, P., Paramelle, B., and Brambilla, C. Basal cell (basaloid) carcinoma of the lung. Hum. Pathol., 23: 993-1003, 1992.
27. Travis, W. D., Linnoila, R. I., Tsokos, M. G., Hitchkock, C. L., Cutler, G. B., Nieman, L., Chrousos, G., Pass, H., and Doppman, J. Neuroendocrine lumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. Am. J. Surg. Pathol., 15: 529-553, 1991.
28. IKK4a/MTS1 gene. Oncogene, 15: 2475-2481, 1997.
29. Gouyer, V., Gazzeri, S., Bolon, I., Drevet, C., Brambilla, C., and Brambilla, E. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am. J. Respir. Cell Mol. Biol., 17: 1-9, 1997.
30. Pollock, P., Pearson, J. V., and Hayward. N. K. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitution. Genes Chromosomes Cancer, 15: 77-88, 1996.
31. Brambilla, E., Gazzeri, S., Moro, D., Caron De Fromentel, C., Gouyer, V., Jacrot, M., and Brambilla, C. Immunohistochemical study of p53 in human lung carcinoma. Am. J. Pathol., 143: 199-210, 1993.
32. Koh, J., Enders, G. H., Dynlacht, B. D., and Harlow, E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (Lond.), 375: 506-510, 1995.
33. Gazzeri, S., Brambilla, E., Caron De Fromentel, C., Gouyer, V., Moro, D., Perron, P., Berger, F., and Brambilla, C. p53 genetic abnormalities and myc activation in human lung carcinoma. Int. J. Cancer, 58: 24-32, 1994.
34. Takahashi, T., Takahashi, T., Suzuki, H., Hida, T., Sekido, Y., Ariyoshi, Y., and Ueda, R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene, 6: 1775-1778, 1991.
35. D'Amico, D., Carbone, D., Mitsudomi, T., Nau, M., Fedorko, J., Russel, E., Johnson, B., Buchhagen, D., Bodner, S., Phelps, R., Gazdar, A., and Minna, J. D. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene, 7: 339-346, 1992.
36. Brown, D. R., Thomas, C. A., and Deb, S. P. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J., 17: 2513-2525, 1998.
37. Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., La Thangue, N. B., and Kouzarides, T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature (Lond.), 375: 691-694, 1995.
38. Xiao, Z. X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J., Sellers, W. R., and Livingston, D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature (Lond.), 375: 694-698, 1995.